Last reviewed · How we verify
AVX754
At a glance
| Generic name | AVX754 |
|---|---|
| Also known as | apricitabine |
| Sponsor | Avexa |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Study of the Efficacy and Safety of Apricitabine, a New NRTI, to Treat Drug-resistant HIV Infection (PHASE2, PHASE3)
- Pharmacokinetics of Apricitabine and Tipranavir When Dosed Alone or Together (PHASE1)
- A Long Term, Safety Study of Apricitabine in HIV-infected Subjects (PHASE2)
- A Study to Investigate the Cardiovascular Safety of Apricitabine in Healthy Subjects (PHASE1)
- A Long Term Safety Study of Apricitabine in HIV-infected Patients (PHASE3)
- AVX754 (a New Nucleoside Reverse Transcriptase Inhibitor [NRTI]) to Treat Drug-resistant HIV (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AVX754 CI brief — competitive landscape report
- AVX754 updates RSS · CI watch RSS
- Avexa portfolio CI